1
/
of
0
FDA Drug Approval, N205422, REXULTI
FDA Drug Approval, N205422, REXULTI
Regular price
$149.00 USD
Regular price
Sale price
$149.00 USD
Unit price
/
per
NDA: 205422
Company: OTSUKA
Drug Name: REXULTI
Active Ingredients: BREXPIPRAZOLE
Strength: 4MG
Dosage Form/Route: TABLET;ORAL
Action Date: 07/10/2015
Marketing Status: Prescription
Submission Classification: Type 1 - New Molecular Entity
Company: OTSUKA
Drug Name: REXULTI
Active Ingredients: BREXPIPRAZOLE
Strength: 4MG
Dosage Form/Route: TABLET;ORAL
Action Date: 07/10/2015
Marketing Status: Prescription
Submission Classification: Type 1 - New Molecular Entity
Couldn't load pickup availability
- Status: Pending Fast-Track Request
- Delivery: Approximately 1 to 2 weeks
NOTE: This document is not currently in our library. Upon purchase, we will request the document from the FDA FOIA office. Learn more about Fast-Track Requests here.
View full details